Nuvelo Announces First Quarter 2008 Financial Results and Updated 2008 Outlook Conference Call

SAN CARLOS, Calif., April 28 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it will hold a conference call and virtual webcast to discuss its first quarter 2008 financial results and provide an updated outlook for 2008 on Thursday, May 8, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode 43639045. A telephone replay of the conference call will be available through Thursday, May 22, 2008. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode 43639045.

This call is being webcast by Thomson/CCBN and will include a virtual slide presentation. The webcast can be accessed via Nuvelo's website at http://www.nuvelo.com and is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

SOURCE Nuvelo, Inc.